PMID- 32385217
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 0973-7138 (Electronic)
IS  - 0250-5991 (Linking)
VI  - 45
DP  - 2020
TI  - MiR-140-3p inhibits natural killer cytotoxicity to human ovarian cancer via 
      targeting MAPK1.
LID - 66 [pii]
AB  - Natural killer (NK) cells have pivotal role in immunotherapy of human ovarian 
      cancer (OC). Although microRNAs (miRNAs) participate in dysfunction of NK cells, 
      how and whether miR-140-3p regulates cytotoxicity of NK cells in OC are 
      uncertain. miR-140-3p and mitogen activated protein kinase 1 (MAPK1) abundances 
      were examined via quantitative real-time polymerase chain reaction or western 
      blot. Tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) abundances were 
      examined via enzyme linked immunosorbent assay. NK cytotoxicity to OC was 
      evaluated via lactate dehydrogenase release. The relevance of miR-140-3p and 
      MAPK1 was proved via luciferase activity analysis. Murine xenograft experiment 
      was applied to assess the function of miR-140-3p on NK cytotoxicity. miR-140-3p 
      was elevated and MAPK1 was declined in NK cells from OC patients, while the 
      levels were reversed after treatment of interleukin-2 (IL-2). MiR-140-3p addition 
      mitigated IFN-gamma and TNF-alpha production induced via IL-2 as well as NK-92 
      cytotoxicity to OC cells. Additionally, MAPK1 was negatively regulated via 
      miR-140-3p and ablated the influence of miR140-3p on cytotoxicity, cytokines 
      levels. Besides, miR-140-3p enrichment facilitated tumor growth via suppressing 
      function of NK cells in a xenograft model. miR-140-3p suppressed NK cytotoxicity 
      to OC cells via mediating MAPK1, indicating a new avenue of ameliorating NK cells 
      function for OC treatment.
FAU - Wang, Jiaying
AU  - Wang J
AD  - Department of Gynecology and Obstetrics, The affiliated Hospital of Medical 
      School of Ningbo University, Ningbo 31500, Zhejiang, China.
FAU - Zhu, Miaohua
AU  - Zhu M
FAU - Zhou, Xiaoming
AU  - Zhou X
FAU - Wang, Tingting
AU  - Wang T
FAU - Xi, Yanni
AU  - Xi Y
FAU - Jing, Zhang
AU  - Jing Z
FAU - Xi, Wenjin
AU  - Xi W
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Biosci
JT  - Journal of biosciences
JID - 8100809
RN  - 0 (Antagomirs)
RN  - 0 (IFNG protein, human)
RN  - 0 (Interleukin-2)
RN  - 0 (MicroRNAs)
RN  - 0 (Mirn140 microRNA, human)
RN  - 0 (Ribonucleotides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
SB  - IM
MH  - Animals
MH  - Antagomirs/genetics/metabolism
MH  - Base Pairing
MH  - Base Sequence
MH  - Case-Control Studies
MH  - Cell Line, Tumor
MH  - Coculture Techniques
MH  - *Cytotoxicity, Immunologic
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Interferon-gamma/genetics/immunology
MH  - Interleukin-2/pharmacology
MH  - Killer Cells, Natural/*immunology/pathology
MH  - Mice
MH  - MicroRNAs/agonists/antagonists & inhibitors/*genetics/immunology
MH  - Mitogen-Activated Protein Kinase 1/*genetics/immunology
MH  - Ovarian Neoplasms/*genetics/immunology/pathology
MH  - Primary Cell Culture
MH  - Ribonucleotides/genetics/metabolism
MH  - Signal Transduction
MH  - Tumor Necrosis Factor-alpha/genetics/immunology
MH  - Xenograft Model Antitumor Assays
EDAT- 2020/05/10 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/05/10 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - 66 [pii]
PST - ppublish
SO  - J Biosci. 2020;45:66.